|
|
Research Management and Support
|
RMS ES 2018
|
$340,640,887
|
$4,224,935
|
N/A
|
National Institutes of Health
|
|
|
IGF::OT::IGF Division of Cancer Prevention, Information Technology and Informatics Support Option 1 Period of Performance 09/22/2017 - 09/21/2019
|
261201500002B
|
$3,351,670
|
$1,106,051
|
-, -
|
INFORMATION MANAGEMENT SERVICES, INC.
|
|
|
Exercise Option 1 Preclinical Efficacy Evaluation of the Lipid-Based SMEDDS Formulation of DIM, BR-9001,
|
261201500042I
|
$973,931
|
$973,931
|
-, -
|
IIT RESEARCH INSTITUTE
|
|
|
IGF::OT::IGF Topic 345 - SBIR Phase II: RadTox - Measuring Radiation Toxicity using Circulating DNA
|
261201800036C
|
$1,999,984
|
$999,992
|
-, -
|
DIACARTA, LLC
|
|
|
NCI EARLY DETECTION RESEARCH NETWORK: BIOMARKER STANDARDIZATION LABORATORY
|
ACN15005-001
|
$600,000
|
$450,000
|
-, -
|
NATIONAL INSTITUTE OF STANDARD
|
|
|
DOE PNNL
|
ACN15006-001
|
$800,000
|
$800,000
|
-, -
|
UNITED STATES DEPT OF ENERGY
|
|
|
EARLY DETECTION RESEARCH NETWORK (EDRN) BIOMARKER REFERENCE LABORATORY
|
ACN17005-001
|
$498,644
|
$498,645
|
-, -
|
UNIFORM THE SERVICES UNIVERSIT
|
|
|
Preclinical analyses of advanced prostate cancer in genetically-engineered mice
|
2R01CA173481-06
|
$385,883
|
$385,883
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Molecular mechanisms of prostate cancer metastasis
|
5R01CA183929-04
|
$366,000
|
$366,000
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
|
5U54CA163069-08
|
$1,347,488
|
$188,648
|
ADUNYAH, SAMUEL
|
MEHARRY MEDICAL COLLEGE
|
|
|
Novel Combinatorial Therapeutic Approach for Prostate Cancer
|
5R03CA219336-02
|
$74,250
|
$74,250
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
|
Leveraging polyamine metabolic stress as a novel therapy for prostate cancer
|
4K00CA212455-03
|
$69,749
|
$69,749
|
AFFRONTI, HAYLEY
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-04S1
|
$145,357
|
$11,629
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
5U10CA180791-05
|
$922,200
|
$73,776
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
Targeting galectin-3 to overcome drug resistance in metastatic prostate cancer therapy
|
1R43CA228813-01A1
|
$300,000
|
$300,000
|
AHMED, HAFIZ
|
GLYCOMANTRA, INC.
|
|
|
ATBC Study
|
ZIA CP010195 03031
|
$738,165
|
$177,160
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
|
SELECT and Prostate Cancer Prevention Trial (PCPT)
|
ZIA CP010221 10405
|
$19,710
|
$19,710
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
|
EDRN Prostate Cancer Metabolomics Profiling
|
ZIA CP010221 10713
|
$78,839
|
$78,839
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
|
NIH Clinical Center Pre-prostatectomy vitamin D supplementation intermedicate bio
|
ZIA CP010221 10714
|
$315,354
|
$315,354
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
|
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site
|
5U10CA180790-05
|
$1,223,634
|
$97,891
|
ALBERTS, STEVEN
|
MAYO CLINIC ROCHESTER
|
|
|
Commercialization of a proprietary Ga-68 PSMA-targeted drug for PET imaging in recurrent prostate cancer
|
1R44CA233140-01
|
$299,412
|
$299,412
|
ALEXOFF, DAVID
|
FIVE ELEVEN PHARMA, INC.
|
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S1
|
$142,498
|
$17,100
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S2
|
$200,000
|
$24,000
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
|
Novel Molecular Therapies of Prostate Cancer
|
5P01CA140043-09
|
$1,222,825
|
$1,222,825
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-49
|
$2,645,581
|
$317,470
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
|
The Role of LSD1 in the Evolution of Castration Resistant Prostate Cancer
|
5R01CA178610-05
|
$317,240
|
$317,240
|
ALUMKAL, JOSHI
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
|
Maryland Prostate Cancer Case-Control Study
|
ZIA BC 010499
|
$399,760
|
$399,760
|
Ambs, Stefan
|
CCR (NCI)
|
|
|
The Molecular Profile of Prostate Tumors in African-American Men
|
ZIA BC 010624
|
$149,910
|
$149,910
|
Ambs, Stefan
|
CCR (NCI)
|
|
|
Non-coding RNAs as Prognostic and Diagnostic Markers in Prostate Cancer
|
ZIA BC 010886
|
$49,970
|
$49,970
|
Ambs, Stefan
|
CCR (NCI)
|
|
|
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
|
ZIA BC 010030
|
$753,084
|
$37,654
|
Ambudkar, Suresh
|
CCR (NCI)
|
|
|
Role of histone kinase VprBP in gene silencing: mechanisms, targets, and regulation
|
5R01CA201561-03
|
$377,438
|
$124,555
|
AN, WOOJIN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
|
Clinical bacterial isolate engineered as an immunotherapy for prostate cancer
|
5F30CA203472-03
|
$49,524
|
$49,524
|
ANKER, JONATHAN
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
|
Hutchinson Center as Lead Academic Participating Site (U10)
|
5U10CA180828-05
|
$605,293
|
$30,265
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Predicting the Presence of Clinically Significant Prostate Cancer using Multiparametric MRI and MR-US Fusion Biopsy
|
1R21CA220352-01A1
|
$195,568
|
$195,568
|
ARNOLD, COREY
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
|
Role of GPR120 and Macrophages in Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer
|
1R01CA231219-01
|
$444,969
|
$444,969
|
ARONSON, WILLIAM
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
|
Stanford Cancer Institute
|
3P30CA124435-11S1
|
$248,520
|
$9,941
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
|
Stanford Cancer Institute
|
3P30CA124435-11S2
|
$171,518
|
$6,861
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
|
Stanford Cancer Institute
|
5P30CA124435-11
|
$3,334,464
|
$133,379
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
3P30CA142543-09S1
|
$249,371
|
$12,469
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
5P30CA142543-09
|
$2,480,000
|
$124,000
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
|
DNA repair alterations in metastatic prostate cancer: functional and therapeutic implications
|
1R01CA230516-01
|
$564,655
|
$564,655
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
|
Cancer Center Support Grant
|
2P30CA082103-19
|
$7,954,381
|
$715,894
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
|
Cancer Center Support Grant
|
3P30CA082103-19S1
|
$84,000
|
$7,560
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
|
Cancer Center Support Grant
|
3P30CA082103-19S2
|
$206,488
|
$18,584
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
|
Cancer Center Support Grant
|
3P30CA082103-19S3
|
$257,838
|
$23,205
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
|
Radiolabeled FASN Inhibitors for PET Imaging
|
5R21CA213157-02
|
$176,883
|
$176,883
|
BABICH, JOHN
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
|
Risk-stratification of Prostate Cancers via Field Carcinogenesis Nanocytology
|
5R01CA200064-04
|
$628,861
|
$628,861
|
BACKMAN, VADIM
|
NORTHWESTERN UNIVERSITY
|
|
|
IGF::OT::IGF TOPICAL EGCG (VEREGEN) IN CERVICAL DYSPLASIA, A FEASIBILITY CLINICAL TRIAL
|
261201200033I
|
$1,922,742
|
$634,505
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
2P30CA014520-44
|
$4,590,130
|
$229,507
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
3P30CA014520-44S1
|
$250,000
|
$12,500
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
Total relevant funding to Prostate for this search: $239,139,126
|
